Literature DB >> 28049650

Inflammation as a Therapeutic Target To Improve Vascular Function in Kidney Disease.

Carl P Walther1, Sankar D Navaneethan2,3.   

Abstract

Entities:  

Keywords:  Inflammation; chronic kidney disease; interleukins; vascular disease

Mesh：

Substances：

Year:  2017        PMID： 28049650      PMCID： PMC5328175          DOI： 10.1681/ASN.2016111173

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  8 in total

1.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Authors:  Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

2.  Trial quality in nephrology: how are we measuring up?

Authors:  Suetonia C Palmer; Michela Sciancalepore; Giovanni F M Strippoli
Journal:  Am J Kidney Dis       Date:  2011-09       Impact factor: 8.860

3.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

Authors:  Paul M Ridker; Tom Thuren; Andrew Zalewski; Peter Libby
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

4.  Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.

Authors:  Ignatios Ikonomidis; Stavros Tzortzis; Ioanna Andreadou; Ioannis Paraskevaidis; Chrysoula Katseli; Pelagia Katsimbri; George Pavlidis; John Parissis; Dimitrios Kremastinos; Maria Anastasiou-Nana; John Lekakis
Journal:  Circ Cardiovasc Imaging       Date:  2014-04-29       Impact factor: 7.792

5.  IL-1β receptor antagonist reduces inflammation in hemodialysis patients.

Authors:  Adriana M Hung; Charles D Ellis; Ayumi Shintani; Cindy Booker; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2011-02-10       Impact factor: 10.121

6.  Inflammation and Progression of CKD: The CRIC Study.

Authors:  Richard L Amdur; Harold I Feldman; Jayanta Gupta; Wei Yang; Peter Kanetsky; Michael Shlipak; Mahboob Rahman; James P Lash; Raymond R Townsend; Akinlolu Ojo; Akshay Roy-Chaudhury; Alan S Go; Marshall Joffe; Jiang He; Vaidyanathapuram S Balakrishnan; Paul L Kimmel; John W Kusek; Dominic S Raj
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

7.  Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Edward H Giannini; Andreas O Reiff; Yukiko Kimura; Suzanne Li; Philip J Hashkes; Carol A Wallace; Karen B Onel; Dirk Foell; Richard Wu; Stephanie Biedermann; Jennifer D Hamilton; Allen R Radin
Journal:  Arthritis Rheum       Date:  2013-09

Review 8.  Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.

Authors:  Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 10.121
  8 in total
  2 in total

1.  Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels.

Authors:  Shulin Li; Yanping Wang; Lu Chen; Zhuojun Wang; Guodong Liu; Bangjie Zuo; Caixia Liu; Dong Sun
Journal:  J Mol Med (Berl)       Date:  2019-03-28       Impact factor: 4.599

2.  Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.

Authors:  Xingxing An; Guangneng Liao; Younan Chen; Ai Luo; Jingping Liu; Yujia Yuan; Lan Li; Lichuan Yang; Hong Wang; Fang Liu; Guang Yang; Shounan Yi; Yuanmin Li; Jingqiu Cheng; Yanrong Lu
Journal:  Stem Cell Res Ther       Date:  2019-12-02       Impact factor: 6.832
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.